Splenic irradiation in the palliation of patients with lymphoproliferative and myeloproliferative disorders

Paulino, Arnold C.; Reddy, Sarada P.

doi:10.1177/104990919601300613

Cited by 23 publications

(22 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Literatürler incelendiğinde tedavi etkinliğini değerlendiren birkaç çalışmaya rastlanmaktadır [5][6][7][8][9][10]. Paulino and Reddy [7] splenik RT sonuçlarını değerlendirdikleri çalışmada lenfoproliferatif ve kronik myeloproliferatif hastalık tanısı ile izlenen hastalardaki splenomegalinin %60 olguda, abdominal ağrının ise olguların %90'ında azaldığını gözlemlemişlerdir. Bu çalışmanın sonucunda splenik RT'nin kısa süreli de olsa splenomegalinin neden olduğu ağrı palyasyonunda etkili olduğu gösterilmiştir.…”

Section: Discussionunclassified

İdiyopatik myelofibrozis tanılı olguda adaptif splenik radyoterapi

Ay¹,

Eren²

2012

CMJ

View full text Add to dashboard Cite

Özetİdiyopatik myelofibrosis kronik myeloproliferatif bir hastalıktır. Kronik myeloproliferatif hastalıklar myeloid hücre büyümesi ile ilişkili klonal kök hücre bozukluklarıdır. Kemik iliği yetersizliğine bağlı görülen ekstramedüller hematopoez ve artmış eritropoez sonucu masif splenomegali gelişir, bu da anemi ve abdominal rahatsızlığa yol açarak morbiditeye sebep olur. Splenik radyoterapi masif splenomegaliye bağlı görülen abdominal ağrı, anemi ve trombositopeni gibi semptomları palyasyon amacıyla önerilmektedir. Bu çalışmada idiyopatik myelofibrozis tanısı ile takip edilen 59 yaşındaki erkek olgu değerlendirildi. Masif splenomegaliye bağlı narkotik analjezik kullanımı gerektiren şiddetli ağrı, hipersplenizmin neden olduğu ciddi trombositopeni ve tekrarlayan transfüzyon ihtiyacı sonucu palyasyon amacı ile haftada 2 fraksiyon toplamda 6 fraksiyon olacak şekilde haftalık artan dozlarda splenik RT uygulandı. Tedavi sonrası olgunun abdominal ağrısında %100 palyasyon sağlandığı görüldü. Splenik RT, semptomatik splenomegalinin palyatif tedavisinde etkin bir tedavi modalitesi olarak göz önünde bulundurulmalıdır. Anahtar sözcükler: İdiyopatik myelofibrozis, splenomegali, splenik radyoterapi AbstractIdiopathic myelofibrosis is a chronic myeloproliferative disorder. Chronic myeloprolipherative disorders are clonal stem cell disorders associated with myeloid cell growth . Extramedullary hematopoiesis in the bone marrow deficiency and increased erythropoiesis resultin massive splenomegaly which then lead to anemia and abdominal discomfort which are major causes of morbidity in these cases. Splenic radiotherapy is recommended for palliation of symptoms such as abdominal pain, anemia and thrombocytopenia due to massive splenomegaly. In this study, a 59-year-old male patient with a diagnosis of idiopathic myelofibrosis was evaluated. Splenic radiotherapy was applied to him in 2 fractions per week with increasing doses for a total of 6 fractions as he had massive splenomegaly, severe pain requiring narcotic analgesic use, and had repeated need for transfusion caused by severe thrombocytopenia due to hypersplenism His abdominal pain palliation was achieved by 100% after treatment. . Splenic radiotherapy should be considered as an effective treatment modality for palliative treatment of symptomatic splenomegaly.

show abstract

Section: Discussionunclassified

İdiyopatik myelofibrozis tanılı olguda adaptif splenik radyoterapi

Ay¹,

Eren²

2012

CMJ

View full text Add to dashboard Cite

show abstract

“…In blood culture of many patients with suspected sepsis, gram positive bacterium Streptococcus pneumoniae has been isolated in 50-90% of the time [23,25]. Yet the another retrospective study, in 66% of the cases pneumococcus were responsible for sepsis after splenectomy [25]. Pneumococcal infections can be seen in all age groups but spesi ically in the older ages, rate of infection rises.…”

Section: Paliative Radiation Therapy To Spleenmentioning

confidence: 99%

“…Streptococcus pneumoniae, Haemophilus in luenzae and Neisseria meningitidis are the most common encapsulated microorganisms that have been found to be responsible for sepsis after splenectomy [19][20][21][22][23]. In blood culture of many patients with suspected sepsis, gram positive bacterium Streptococcus pneumoniae has been isolated in 50-90% of the time [23,25]. Yet the another retrospective study, in 66% of the cases pneumococcus were responsible for sepsis after splenectomy [25].…”

Section: Paliative Radiation Therapy To Spleenmentioning

confidence: 99%

“…Hypofractionated treatments or intermittant treatment schemes were administered to minimize acute hematologic toxicity. Today, For splenic RT, daily doses of 0.5-1 Gy, two or three fractions per week (intermittent or hypofractionated) and total dose of 3.5-6 Gy have been accepted generally [31,33,35,[38][39][40]. In the previous work of elderly patients with myeloproliferative diseases who developed symptomatic splenomegaly, we used palliative RT 2-3 fractions per week, at a daily dose of 0.5 Gy, mean total dose of 7.5 Gy.…”

Section: The Spleen In Radiation Dose-volume Relationshipmentioning

confidence: 99%

“…In particular, patients in the terminal stage, or conservatively followed patients are best candidates for RT due to reduction in narcotic use. Also decreased costs and lower toxicity may it an preferrable option [8,[29][30][31][32][33].…”

Section: Paliative Radiation Therapy To Spleenmentioning

confidence: 99%

See 2 more Smart Citations

Which is the best? Palliative Radiation Therapy to Spleen or Splenectomy

Cihan¹

2018

J Radiol Oncol

View full text Add to dashboard Cite

Animal Models of Systemic Lupus Erythematosus (SLE) and Ex Vivo Assay Design for Drug Discovery

Seavey¹,

Lu²,

Stump³

2011

CP Pharmacology

View full text Add to dashboard Cite

Systemic Lupus Erythematosus (SLE) is a debilitating and often fatal autoimmune disease that involves multiple organ systems. It can develop for years before being diagnosed. Current treatments for SLE usually involve the use of cytotoxic or immunosuppressive agents that can lead to infection or cancer. The design of appropriate models and assays will determine the efficiency and speed with which an investigator can test a new chemical entity (NCE) or expect results to move a drug discovery program forward. This unit describes a series of preclinical assays for the identification of new agents for the treatment of SLE. Most importantly, this unit will guide the reader through a step-by-step process to select appropriate models, validation drugs, and readouts, depending on the objective of the study. The reader will acquire a working knowledge of what models are available and the potential advantages and disadvantages of each, including ex vivo assays relevant to the discovery of new SLE therapeutics.

show abstract

Splenic irradiation in the palliation of patients with lymphoproliferative and myeloproliferative disorders

Cited by 23 publications

References 4 publications

İdiyopatik myelofibrozis tanılı olguda adaptif splenik radyoterapi

İdiyopatik myelofibrozis tanılı olguda adaptif splenik radyoterapi

Which is the best? Palliative Radiation Therapy to Spleen or Splenectomy

Animal Models of Systemic Lupus Erythematosus (SLE) and Ex Vivo Assay Design for Drug Discovery

Contact Info

Product

Resources

About